drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy (CAR T cells)
drug_description
Allogeneic BCMA-directed UCAR-T cells; genetically modified T cells engineered with a CAR targeting B-cell maturation antigen (BCMA). Administered by cell infusion to recognize BCMA+ malignant plasma cells and induce T-cell cytotoxicity and cytokine release.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic T cells engineered with a chimeric antigen receptor targeting BCMA bind BCMA on malignant plasma cells, triggering CAR-mediated T‑cell activation, perforin/granzyme‑dependent cytotoxicity, and cytokine release to lyse BCMA‑positive myeloma/plasma cell leukemia cells; designed as an off‑the‑shelf (UCAR) product.
drug_name
CT0594 (BCMA-UCAR-T)
nct_id_drug_ref
NCT05822037